Together with the aforementioned high prevalence of NAFLD in morbidly obese individuals, the prevalence of Hp seropositivity in these patients is also higher (a 1.7-fold increased probability of having Hp-I) compared with nonobese controls [17]. Here, HP is linked to metabolic dysfunction-associated steatotic liver disease.